Figure 4. The context in which antigen is presented may affect recall potential of Thy1.1⁺ CD8⁺ antigen specific T cells.

A) Experimental design for generation of secondary effectors and assessments. OVA-specific monoclonal TCR-transgenic Thy1.1⁺ T cells were transferred into C57BL/6 mice at day -1. The cells were then exposed OVA antigen in vivo by OVA expressing gHV or skin grafts at day zero. Mesenteric lymph nodes were harvested four weeks after primary challenge for baseline assessments and draining popliteal lymph nodes were harvested 5 days post footpad rechallenge. B) Representative flow cytometric staining of Thy1.1⁺ CD8⁺ antigen-specific T cells at four weeks post priming and five days after rechallenge. C) The frequency of Thy 1.1⁺ CD8⁺ antigen-specific T cells harvested after gHV and skin graft priming was not statistically different between priming environments. D) The number of Thy 1.1⁺ CD8⁺ antigen-specific T cells harvested after gHV and skin graft priming was not statistically different between priming environments. E) The fold change in number from average numbers of Thy 1.1⁺ CD8⁺ antigen-specific T cells was not statistically different, but there appears to be a trend toward a greater fold change in the number of Thy 1.1⁺ CD8⁺ antigen-specific T cells primed by skin graft. Representative of 3 independent experiments with 5-10 mice/group. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns = not significant.